Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab – a cross-sectional study from the BioDay registry

Figures & data

Table 1. Basic characteristics of total study population (n = 104).

	n = 104
Men, n (%)	58 (55.8)
Age at questionnaire completion (year)
Median (IQR)	46 (24.5)
Mean (SD)	46.1 (16.4)
EASI score at baseline^a
Median (IQR)	12.6 (8.5)
Mean (SD)	14.1 (8.6)
Missing, n (%)	6 (5.8)
IGA score at baseline^a
Median (IQR)	3 (1)
Mean (SD)	3.0 (0.8)
Missing, n (%)	1 (1.0)
DLQI score at baseline^a
Median (IQR)	13 (9)
Mean (SD)	12.9 (6.9)
Missing, n (%)	5 (4.8)
POEM score at baseline^a
Median (IQR)	20 (9)
Mean (SD)	19.0 (6.6)
Missing, n (%)	3 (2.9)
Weekly average pruritus NRS at baseline^a
Median (IQR)	7 (2)
Mean (SD)	6.6 (2.4)
Missing, n (%)	1 (1.0)
Weekly average pain NRS at baseline^a
Median (IQR)	2 (5)
Mean (SD)	3.3 (3.0)
Missing, n (%)	1 (1.0)
Atopic/allergic diseases at baseline^a, n (%)
Allergic rhinitis	61 (58.7)
Asthma	53 (51.0)
Allergic conjunctivitis	58 (55.8)
Food allergy	42 (40.4)
History of ≥ 2 oral immunosuppressive treatments at baseline^a, n (%)	54 (51.9)

DLQI: Dermatology Life Quality Index; EASI: Eczema Area and Severity Index; IGA: Investigator Global Assessment; IQR: interquartile range; NRS: Numerical Rating Scale; POEM: Patient Oriented Eczema Measure; SD: standard deviation.

^aAt inclusion in the BioDay registry.

Table 2. ADCT, RECAP, and TSQM v.II values, along with closest reported patient reported outcome measures at regular BioDay visits.

	n = 104
ADCT score
Median (IQR)	4 (5)
Mean (SD)	5.1 (3.7)
Missing, n (%)	7 (6.7)
RECAP score
Median (IQR)	5 (6)
Mean (SD)	6.5 (4.7)
Missing, n (%)	5 (4.8)
TSQM v.II global satisfaction score
Median (IQR)	83.3 (25.0)
Mean (SD)	78.9 (16.8)
Missing, n (%)	15 (14.4)
TSQM v.II effectiveness satisfaction score
Median (IQR)	75.0 (16.7)
Mean (SD)	72.8 (20.8)
Missing, n (%)	3 (2.9)
TSQM v.II side effects satisfaction score
Median (IQR)	100.0 (8.3)
Mean (SD)	90.9 (17.0)
Missing, n (%)	10 (9.6)
TSQM v.II convenience satisfaction score
Median (IQR)	72.2 (16.7)
Mean (SD)	73.4 (14.7)
Missing, n (%)	12 (11.5)
Closest DLQI score
Median (IQR)	3 (4.3)
Mean (SD)	4.1 (4.0)
Missing, n (%)	22 (21.2)
Closest POEM score
Median (IQR)	7 (8.3)
Mean (SD)	8.5 (5.8)
Missing, n (%)	22 (21.2)
Closest weekly average pruritus NRS
Median (IQR)	2 (3)
Mean (SD)	3.0 (2.0)
Missing, n (%)	17 (16.3)
Closest weekly average pain NRS
Median (IQR)	0 (2)
Mean (SD)	1.1 (1.6)
Missing, n (%)	17 (16.3)

ADCT: Atopic Dermatitis Control Test; DLQI: Dermatology Life Quality Index; IGA: Investigator Global Assessment; IQR: interquartile range; NRS: Numerical Rating Scale; POEM: Patient Oriented Eczema Measure; RECAP: Recap of Atopic Eczema; SD: standard deviation.

Table 3. Control according to the Atopic Dermatitis Control Tool (ADCT).

	ADCT method 1^a	ADCT method 2^b	ADCT method 3^c
In control, n (%)	69 (66.3)	40 (38.5)	42 (40.4)
Not in control, n (%)	28 (26.9)	57 (54.8)	55 (52.9)
Missing, n (%)	7 (6.7)
Total	104

Definition of ‘not in control’:

^aTotal score on the 6 items is ≥ 7 points.

^bOne of the six answers is: item 1 ≥ Moderate; item 2 ≥ 3–4 days; item 3 ≥ Moderately; item 4 ≥ 1 or 2 nights; item 5 ≥ Moderate; item 6 ≥ Moderate.

^cOne of the four first answers is: item 1 ≥ Moderate; item 2 ≥ 3–4 days; item 3 ≥ Moderately; item 4 ≥ 1 or 2 nights.

Figure 1. Treatment Satisfaction Questionnaire for Medication (TSQM) measures for dupilumab in daily practice. Whiskers represent 10–90th percentiles.